7/24/2013

An FDA panel voted 7-6 in favor of approving UCB's certolizumab as a treatment for some types of inflammatory arthritis including ankylosing spondylitis, axial spondyloarthritis and nonradiographic axial spondyloarthritis. The drug is already approved for rheumatoid arthritis.

Full Story:
Reuters

Related Summaries